HTA114 Review of Health Technology Assessment (HTA) and Recommendations for the Introduction of Higher-Valency Pneumococcal Conjugated Vaccine (PCV) in 4 European Countries, The United-Kingdom (UK), and The United-States (US)
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1573
https://www.valueinhealthjournal.com/article/S1098-3015(22)03778-0/fulltext
Title :
HTA114 Review of Health Technology Assessment (HTA) and Recommendations for the Introduction of Higher-Valency Pneumococcal Conjugated Vaccine (PCV) in 4 European Countries, The United-Kingdom (UK), and The United-States (US)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03778-0&doi=10.1016/j.jval.2022.09.1573
First page :
Section Title :
Open access? :
No
Section Order :
11123